Mineralys Therapeutics (MLYS) Liabilities and Shareholders Equity (2022 - 2026)

Mineralys Therapeutics has disclosed Liabilities and Shareholders Equity across 5 years of filings, most recently posting $652.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $652.9 million, up 83.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 96.09% YoY), and the FY2025 annual result was $661.8 million, up 221.42% from the prior year.
• Liabilities and Shareholders Equity came in at $652.9 million for Q1 2026 at Mineralys Therapeutics, down from $661.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $661.8 million in Q4 2025 to a low of $114.4 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $312.5 million (2023), against an average of $356.2 million.
• Across the five-year window, Liabilities and Shareholders Equity declined 18.17% in 2024 and surged 221.42% in 2025, its largest moves.
• Mineralys Therapeutics' Liabilities and Shareholders Equity stood at $114.4 million in 2022, then soared by 119.88% to $251.6 million in 2023, then decreased by 18.17% to $205.9 million in 2024, then soared by 221.42% to $661.8 million in 2025, then slipped by 1.35% to $652.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $652.9 million (Q1 2026), $661.8 million (Q4 2025), and $599.9 million (Q3 2025), per Business Quant data.